Literature DB >> 12832713

Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.

Nicolino Ruperto1, Angelo Ravelli, Kevin J Murray, Daniel J Lovell, Boel Andersson-Gare, Brian M Feldman, Stella Garay, Wietse Kuis, Claudia Machado, Lauren Pachman, Anne-Marie Prieur, Lisa G Rider, Earl Silverman, Elena Tsitsami, Pat Woo, Edward H Giannini, Alberto Martini.   

Abstract

OBJECTIVE: To identify preliminary core sets of outcome variables for disease activity and damage assessment in juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM).
METHODS: Two questionnaire surveys were mailed to 267 physicians from 46 different countries asking each member to select and rank the response variables used when assessing clinical response in patients with JSLE or JDM. Next, 40 paediatric rheumatologists from 34 countries met and, using the nominal group technique, selected the domains to be included in the disease activity and damage core sets for JSLE and JDM.
RESULTS: A total of 41 response variables for JSLE and 37 response variables for JDM were selected and ranked through the questionnaire surveys. In the consensus conference, domains selected for both JSLE and JDM activity or damage core sets included the physician and parent/patient subjective assessments and a global score tool. Domains specific for JSLE activity were the immunological tests and the kidney function parameters. Concerning JDM, functional ability and muscle strength assessments were indicated for both activity and damage core sets, whereas serum muscle enzymes were included only in the activity core set. A specific paediatric domain called 'growth and development' was introduced in the disease damage core set for both diseases and the evaluation of health-related quality of life was advised in order to capture the influence of the disease on the patient lifestyle.
CONCLUSIONS: We developed preliminary core sets of measures for disease activity and damage assessment in JSLE and JDM. The prospective validation of the core sets is in progress.

Entities:  

Mesh:

Year:  2003        PMID: 12832713     DOI: 10.1093/rheumatology/keg403

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  70 in total

1.  Toward the development of criteria for global flares in juvenile systemic lupus erythematosus.

Authors:  Hermine I Brunner; Marisa S Klein-Gitelman; Gloria C Higgins; Sivia K Lapidus; Deborah M Levy; Anne Eberhard; Nora Singer; Judyann C Olson; Karen Onel; Marilynn Punaro; Laura Schanberg; Emily von Scheven; Jun Ying; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

2.  Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.

Authors:  Adam M Huber; Angela B Robinson; Ann M Reed; Leslie Abramson; Sharon Bout-Tabaku; Ruy Carrasco; Megan Curran; Brian M Feldman; Harry Gewanter; Thomas Griffin; Kathleen Haines; Mark F Hoeltzel; Josephine Isgro; Philip Kahn; Bianca Lang; Patti Lawler; Bracha Shaham; Heinrike Schmeling; Rosie Scuccimarri; Michael Shishov; Elizabeth Stringer; Julie Wohrley; Norman T Ilowite; Carol Wallace
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

Review 3.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

4.  PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.it.

Authors:  N Ruperto; P Garcia-Munitis; L Villa; M Pesce; A Aggarwal; A Fasth; T Avcin; S-C Bae; Z Balogh; C Li; J De Inocencio; M Dibra; P Dolezalova; Y El Miedany; B Flato; M Harjacek; H-I Huppertz; F Kanakoudi-Tsakalidou; N Wulffraat; P Lahdenne; J A Melo-Gomes; D Mihaylova; S Nielsen; I Nikishina; H Ozdogan; K Pagava; V Panaviene; A-M Prieur; A-M Romicka; I Rumba; N Shafaie; G Susic; S Takei; Y Uziel; R Vesely; P Woo; A Martini
Journal:  Ann Rheum Dis       Date:  2005-03-10       Impact factor: 19.103

5.  EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.

Authors:  S Ozen; N Ruperto; M J Dillon; A Bagga; K Barron; J C Davin; T Kawasaki; C Lindsley; R E Petty; A M Prieur; A Ravelli; P Woo
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

6.  The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept.

Authors:  Andrea Golmia; Beni Grinblat; Eduardo Finger; Claudia Klieman; Fernanda Assir; Morton Scheinberg
Journal:  Clin Rheumatol       Date:  2007-10-12       Impact factor: 2.980

Review 7.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 8.  Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization.

Authors:  Nicolino Ruperto; Alberto Martini
Journal:  World J Pediatr       Date:  2008-08       Impact factor: 2.764

Review 9.  Consensus procedures and their role in pediatric rheumatology.

Authors:  Nicolino Ruperto; Silvia Meiorin; Silvia Mirela Iusan; Angelo Ravelli; Angela Pistorio; Alberto Martini
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

10.  Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis.

Authors:  M O Harris-Love; J A Shrader; D Koziol; N Pahlajani; M Jain; M Smith; H L Cintas; C L McGarvey; L James-Newton; A Pokrovnichka; B Moini; I Cabalar; D J Lovell; R Wesley; P H Plotz; F W Miller; J E Hicks; L G Rider
Journal:  Rheumatology (Oxford)       Date:  2008-12-11       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.